ESPAC-3

NCT00058201 📎

Regimen

Experimental
Gemcitabine 1000 mg/m2 weekly x 3 of 4 weeks x 6 cycles.
Control
5-FU 425 mg/m2 + folinic acid 20 mg/m2 d1-5 q4w x 6 cycles (Mayo regimen).

Population

Resected PDAC, R0/R1, post-surgery within 8 weeks, ECOG PS 0-2, 159 centers in Europe/Australasia/Japan/Canada.

Key finding

ESPAC-3 showed gemcitabine and 5-FU/folinic acid are equivalent in OS for adjuvant PDAC therapy, but gemcitabine has a better safety profile. Gemcitabine became the preferred monotherapy backbone globally and the reference control for every adjuvant trial through PRODIGE-24.

Source: PMID 20823433

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.54)